Purified capsular polysaccharides of
The invention relates to capsular polysaccharides of Streptococcus pneumoniae . More specifically, the present invention relates to sized and purified capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C & 35B and process for their preparation.
1 . A pneumococcal conjugate vaccine comprising a 1-cyano-4-dimethylaminopyridine tetrafluoroborate (CDAP)-activated purified capsular polysaccharides from serotype 35B having an average molecular weight between 100 kDa and 500 kDa conjugated to PsaA, wherein the pneumococcal conjugate vaccine comprises a (w/w) percent ratio of protein to polysaccharide (protein/PS) of 0.7 to 1.2.
2 . The pneumococcal conjugate vaccine of claim 1 , wherein the conjugate has an average molecular weight ranging between 500 kDa to 5000 kDa; 1,000 kDa to 10,000 kDa; 1,500 kDa to 15,000 kDa; 2,000 kDa to 20,000 kDa; 2,500 kDa to 25,000 kDa; or 3,000 kDa to 30,000 kDa.
3 . An immunogenic composition comprising at least one glycoconjugate comprising a 1-cyano-4-dimethylaminopyridine tetrafluoroborate (CDAP)-activated purified capsular polysaccharides from serotype 35B having an average molecular weight between 100 kDa and 500 kDa conjugated to PsaA, wherein the glycoconjugate comprises a (w/w) percent ratio of protein to polysaccharide (protein/PS) of 0.7 to 1.2, and wherein the glycoconjugate has an average molecular weight ranging between 500 kDa to 30,000 kDa.
4 . The immunogenic composition of claim 3 , further comprising at least one glycoconjugates from Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 15A, 15B, 15C, 16F, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 31, and 33F, conjugated to PsaA, or CRM197.
5 . The immunogenic composition of claim 4 , wherein the immunogenic composition is an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 25 or more valent pneumococcal conjugate composition.
6 . The immunogenic composition of claim 5 , wherein the immunogenic composition is a 24 valent pneumococcal conjugate composition comprising a purified capsular polysaccharide from serotype 35B and polysaccharides from at least 2 pneumococcal serotypes selected from 2, 15A, and 15C and additional serotypes selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 18C, 19A, 19F, 20A, 20B, 22F, 23F, 24F, and 33F wherein the purified capsular polysaccharide from serotypes 35B is conjugated to PsaA and each of the remaining polysaccharides is conjugated to CRM197 or PsaA.
7 . The immunogenic composition of claim 5 , wherein the immunogenic composition is a 24 valent pneumococcal conjugate composition comprising the purified capsular polysaccharides from pneumococcal serotype 35B; and capsular polysaccharides from at least 1 pneumococcal serotypes selected from 2, 15A, and 15C; and additional serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, and 33F wherein the purified capsular polysaccharide from serotype 35B is conjugated to PsaA and each of the remaining polysaccharides is conjugated to CRM197 or PsaA.
8 . The immunogenic composition of claim 5 , wherein the immunogenic composition is a multivalent pneumococcal conjugate vaccine composition comprising purified capsular polysaccharides from serotype 35B and polysaccharides from at least 2 pneumococcal serotypes selected from 2, 15A, and 15C; and capsular polysaccharides from one or more serotypes selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 20A, 20B, 22F, 23A, 23B, 23F, 24F, and 33F, wherein the purified capsular polysaccharide from serotype 35B is conjugated to PsaA and each of the remaining polysaccharides is conjugated to CRM197 or PsaA.
9 . The immunogenic composition of claim 5 , wherein the immunogenic composition is a 17 valent pneumococcal conjugate vaccine composition comprising polysaccharides from serotypes selected from 1, 2, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 15A, 15C, 18C, 19A, 19F, 23F, and 35B, wherein the purified capsular polysaccharide from serotype 35B is conjugated to PsaA or CRM197.
10 . A method of preventing Streptococcus pneumoniae infection comprising administering the pneumococcal conjugate vaccine of claim 1 to a subject in need thereof.
11 . A method of preventing Streptococcus pneumoniae infection comprising administering the immunogenic composition of claim 3 to a subject in need thereof.